Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11474322 | 0.76 | SMN1; SMN2 (0.41) | TSHR | |
| SCHEMBL7532232 | 0.73 | PDK1 (0.40) | P2RX7TSHR | |
| SCHEMBL7528249 | 0.71 | P2RX7 (0.33) | P2RX7 | |
| SCHEMBL7527042 | 0.70 | KMT2A (0.39) | P2RX7 | |
| Trifluoroacetic Acid SCHEMBL28948223 | 0.68 | GAA (0.43) | RAD52GAAPKMTSHR | |
| Trifluoroacetic Acid SCHEMBL28948230 | 0.68 | GAA (0.43) | RAD52GAAPKMTSHR | |
| Trifluoroacetic Acid SCHEMBL7529674 | 0.67 | AOC3 (0.54) | — | |
| SCHEMBL7530149 | 0.67 | P2RX7 (0.38) | P2RX7 | |
| SCHEMBL7528877 | 0.66 | PDK1 (0.39) | P2RX7TSHR | |
| SCHEMBL28985908 | 0.65 | ALDH1A1 (0.43) | GAAPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | BIOVITRUM AB (SE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002038153-A1 | NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES | BIOVITRUM AB (SE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | AOC3, AOC2, AOC1 | RAD52 395/4885P2RX7 2655/4885GAA 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.